Related Experiment Videos
Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin
R Linn1, I W Klimberg, Z Wajsman
1Department of Surgery, University of Florida, Gainesville.
The Journal of Urology
|May 1, 1989
Summary
Intravesical bacillus Calmette-Guerin (BCG) immunotherapy is effective for bladder cancer. A rare case showed persistent BCG bacteria in granulomas one year post-treatment, a finding not previously reported.
Area of Science:
- Urology
- Oncology
- Infectious Diseases
Background:
- Intravesical bacillus Calmette-Guerin (BCG) is a standard treatment for superficial transitional cell carcinoma of the bladder.
- BCG immunotherapy leverages the host immune system to target cancer cells.
- Acid-fast bacilli are typically found transiently after BCG treatment.
Observation:
- A case study documented persistent acid-fast bacilli within granulomas.
- These granulomas were located in the bladder, prostate, and epididymides.
- The persistence was noted one year after completing intravesical BCG therapy.
Findings:
- This represents the first reported instance of persistent acid-fast bacilli one year post-intravesical BCG administration.
- The presence of bacilli within granulomas suggests a prolonged host response or incomplete eradication.
- The findings challenge the typical understanding of BCG clearance timelines.
Implications:
- This case highlights the potential for long-term persistence of BCG in genitourinary tissues.
- Further investigation is warranted to understand the clinical significance and potential long-term effects of persistent BCG.
- Clinicians should be aware of this rare possibility when managing patients post-BCG therapy.